Company: SMNR
Filing Date: 2025-08-22
Form Type: 425
Source: 0001213900-25-079506
Chunk: 5

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-22
Form: 425
Chunk 5
---
ali specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Denali’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.

<div align='center'>2</div>

No Offer or Solicitation

This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the Business Combination or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits.

| Exhibit 
 No.     
 10.1*   |     | Description                                                                                                                                                            
 Securities Purchase Agreement, dated as of August 20, 2025, by and among Denali Capital Acquisition Corp., Semnur Pharmaceuticals, Inc., and the Buyers party thereto. |
|:--------|:----|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (embedded within the                                                                                                                  
 Inline XBRL document).                                                                                                                                                 |

| * | Certain                                                                                                                               
 schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish a copy 
 of all omitted schedules to the SEC upon its request.                                                                                 |

<div align='center'>3

SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: August 21, 2025 | DENALI CAPITAL ACQUISITION CORP. 
 By:                              | /s/ Lei Huang           |
|:----------------------|:---------------------------------|:------------------------|
|                       | Name:                            | Lei Huang               |
|                       | Title:                           | Chief Executive Officer |

<div align='center'>4</div>